Method of local immunocorrection of female infectious-inflammatory urogenital diseases caused by sexually-transmitted microorganisms

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gynaecology, venereology and immunology, and is applicable for local immunocorrection of female infectious-inflammatory urogenital diseases caused by sexually-transmitted microorganisms. For this purpose, with underlying drug-induced therapy, the immunomodulatory therapy is used from first day of therapy by magnetic laser exposure on a uterus neck. The uterus neck is exposed by a gynecologic speculum which is removed after the procedure is completed. The magnetic laser exposure immediately covers a cervical canal. That is ensured by using a low-intensity laser with variable pulse generation. The magnetic field intensity makes 1.25 T. Pulse train frequency per minute is 30. A pulse interval is 100 msec. Length of the exposure is 5 minutes. The therapeutic course is 10 procedures.

EFFECT: method provides higher complex clinical effectiveness ensured by normalising local immunity factors, namely functional activity recovery of neutrophilic granulocytes of the cervical canal, higher concentration of pro-inflammatory cytokines, immunoglobulins A, M, G in the cervical canal.

3 tbl, 3 ex

 

The invention relates to medicine, namely to gynecology, dermatology and immunology, and is intended for the treatment of infectious-inflammatory diseases of the urogenital tract of women, caused by microorganisms, sexually transmitted diseases by local magnetic effects on the background of a comprehensive drug treatment, as some scholars explain the increase in the number of patients with infectious-inflammatory diseases of the urogenital tract, against the background of significant successful development of gynecology and dermatology, with three dominant factors: a decrease in immune and nonspecific factors of protection of the organism as a whole, reduction of colonization resistance of the reproductive tract, in particular the increasing number of antibiotic-resistant forms of pathogens and their periodic change[2, 4, 6, 12]. Given that in inflammatory diseases of the urogenital tract is most important disorders in the immune system both systemic and local, diverse forms of immune deficiency or preceded by an inflammatory process, or are a consequence of [5,7]. Immune dysfunction occurs when a pathological variant of the immune response becomes stable and, moreover, it is only when yet certain morphological component. In such a situation, usually formed imbalance system of immunoreactivity by factors of natural resistance. This reduces the effectiveness of therapy contributes to the revitalization of conditionally pathogenic microflora, the change of the pathogen, which ultimately can lead to chronic diseases. Restoration of functional activity of local reproductive immunity is a prerequisite for the treatment of infectious-inflammatory diseases of the urogenital tract. In this regard, a clear interest in the use of various tools that can restore local immune imbalance [1, 10, 12]. Currently, much attention is paid to the issues of application of immunostimulatory and immunomodulator therapy for the treatment of inflammatory diseases of the urogenital tract caused by microorganisms, sexually transmitted diseases. Today, the developed method of local application of immunopreparatov ("besten", "Roncoleukin", "Polyoxidonium") [1, 2, 7, 11, 12].

However, in the strategic plan, special attention deserves the study of the potential of physiotherapy therapeutic factors. Clinical and experimental studies conducted in the last decade, indicate the possibility of modulating the immune reactions of the body is under the influence of various physical factors, such as: laser, magnetotherapy, ultrasound, low frequency and so on [9, 10]. Combination therapy using low-level lasers and integrated magnetic radiation has become in recent years one of the most common methods of treatment of inflammatory diseases of the urogenital tract[3, 9, 12].

Studies in recent decades have shown that low-intensity laser irradiation of the near infrared and laser radiation have strong immunomodulatory and immunoprotective properties [10, 12]. After activation of cell cultures of neutrophils, the predominant cells of the secrets of the reproductive tract and engaged in these secrets bactericidal and secretory function, the laser of low intensity electromagnetic millimeter waves marked strengthening of the connections between processes of movement, adhesion, absorption, killing and degranulation with respectively the allocation of biologically active products neutrophilic granulocytes [8].

At the time of writing of this patent application, in the literature there are not numerous and sometimes quite contradictory data on the integrated use of immunomodulator therapy, frequency, low-intensity laser and magnetic therapy for local immune PR is the treatment of infectious-inflammatory diseases of the urogenital tract. In the studied sources we have not met the patterns of use of this method of complex treatment of these diseases treatment on the background of etiotropic therapy. One of the works on the local use of immunomodulatory drugs may be research Isanapura for use of the drug Polyoxidonium in the treatment of patients with urogenital infections by dissolving dry lyophilisate saline solution (0.9% R-rum NaCl at the rate of 0.0001 g (100 mg) in 1 ml of 0.9% R-RA NaCl. One of the drawbacks of this technique it is possible to allocate the limited indications for use of this drug, possible side effects, celebrated by the author [2, 3]. Ahilyabai was used locally only low-intensity laser in the treatment of inflammatory diseases of the urogenital tract with the aim of normalization and recovery of the resident microflora of the cervical canal. The author did not cover the problem of the influence of low-intensity laser radiation on a set of factors influencing the colonization resistance of the reproductive tract and, therefore, were not studied the possibility to use this type of radiation as an immune-modulating means. Magnetic therapy also was previously applied Ragoowansi in complex therapy of inflammatory diseases of the urogenital tract, immunological features of the applications of this type of radiation has not been studied.

The aim of the invention is to improve the efficiency of complex treatment of patients with infectious-inflammatory diseases of the urogenital tract caused by microorganisms, sexually transmitted diseases, through the local magnetic effects.

The essence of the proposed method is that the magnetic-laser therapy applied locally, introducing disposable radiant head directly into the cervical canal from the first day on the background of etiotropic therapy. Exposure was carried out in specially equipped rooms. Position the patient is lying on his back, on the couch or gynecological chair, legs bent at the knee or hip joints and divorced. The magnetic-laser therapy was performed by using the apparatus "Mustang 2000" (NGOs Technique; Moscow) after the analysis of laboratory data, including results of cytological and histological studies, edema of the phenomena of intoxication and exclusion processes in the uterus requiring surgical intervention. Used the following exposure parameters: intensity of the magnetic field of 1.25 Tesla; frequency series of pulses per minute 30, the interval between the pulses of 100 MS; the wavelength 0.63 μm, the mode of the radiation pulse, the wavelength of 0.63 µm. Localization and effect: radiant head with a single nozzle down to takto neck of the uterus, Nude using a speculum, which during the procedure are removed. The treatment takes 5 minutes Course magnitolazeroterapii is 10 procedures. The magnetic-laser therapy for the correction of local immune dysfunction spent on pharmacotherapy aimed at the elimination of the pathogen. In complex drugs included the following groups of drugs: 1) antibacterial, 2) hyposensitizing, 3) restorative (biogenic stimulators, vitamins). Antibiotics were prescribed empirically, taking into account the results of studying the sensitivity of pathogens, further corrected antibiotic therapy according to the results of bacteriological tests.

The treatment was performed before the onset of the proliferative phase of the inflammatory process, and then combined effect on the inflammation with the use of topical swab on water-soluble base, such as Levomicol". In this combination lasted magnetic effect, leading to immune-modulating effects, strengthening the processes of purification and regeneration of inflammation (due to pronounced macrophage reaction), the prevention of re-contamination nosocomiales flora (by increasing the functional activity of cells of inflammation), and based ointment is and it does not hurt granulation tissue.

Comparable analysis of the claimed and known (traditional, with the use of chemotherapeutic agents "besten", "Roncoleukin", "betalain", "Polyoxidonium")selected for analog and prototype technical solutions, which uses a local impact on the cervix to normalize the local immune factors, showed that the difference of the proposed method is the use as a means conducive to the normalization of the local imbalance of immune factors physiotherapy agent, in particular magnitolazeroterapii, still used as analgesic, anti-inflammatory and increases local blood flow means. Treatment with the use of laser radiation has a more pronounced clinical and immunological effects, as compared to only antibacterial therapy, or in combination antibacterial therapy + local application of drugs "besten", "Roncoleukin", "betalain", "Polyoxidonium". In addition, this type of therapeutic interventions has broader indications for minor contraindications compared with other immunomodulatory agents.

The proposed method corresponds to the criterion "novelty", as in contrast to existing methods, has the following significant distinctive feature of the mi:

1. Proposed by the authors way of local use of laser radiation for correction of dysfunctions factors local anti-infective immunity in patients with infectious-inflammatory diseases of the urogenital tract had a higher clinical and immunological efficacy compared to the basic causal therapies and compared using only the laser or magnetic therapy.

2. In the process of studying the effectiveness of the proposed method defined positive effect of the combined laser radiation on the dynamics of the inflammatory process and the General condition of the patients. Patients in a shorter time observed the disappearance of signs of inflammation, has been more rapid clearance of inflammation from necrotic masses, accelerated the processes of regeneration and stabilization of the General condition of patients, which was manifested in the normalization of laboratory parameters of the patients.

3. According to a study of local immunity in the reproductive tract was set to increase phagocytic activity and intensity of neutrophils of cervical secretion was determined by amplification of oxygendependent killing of phagocytes inflammatory focus in spontaneous and induced tests, nicrosini tetrazolium. We determined the growth options the national reserve of phagocytes, which proves that the effector potential of the cells after combined magnetic effect.

4. Indicators of local immunity in the reproductive tract (the number of immunoglobulins, evaluation of cytokine status after local application of magnitolazeroterapii demonstrated full recovery factors of innate and mucosal immunity in the reproductive tract, modified before the start of therapy.

Due to the presence of these distinctive features in this way, as well as to analyze them together, we can make a conclusion about conformity of the proposed method inventive step and the criterion of "substantial differences".

The inventive method is as follows.

1. Magnetic therapy was performed using an apparatus "Mustang 2000", generating magnetic effects, after analyzing data from laboratory studies of women, excluding contraindications to the use of physical therapy, cupping phenomena of intoxication and exclusion processes in the uterus requiring surgical intervention.

2. Used the following exposure parameters: intensity of the magnetic field of 1.25 Tesla; frequency series of pulses per minute 30, the interval between the pulses of 100 MS; the wavelength 0.63 μm, the mode of the radiation pulse. Position the patient is lying in guinet the ideological chair or on the couch on his back, legs bent at the knee and hip joints and divorced, duration 5 minutes, their number is 10. Impact localization: radiant head with a single nozzle fail to contact the cervix for 5 min, Nude using a speculum.

The authors performed a comprehensive examination and treatment of 55 patients with infectious-inflammatory diseases of the lower section of the reproductive tract, treated using the basic therapy and local impact magneto laser. To evaluate clinical and immunological effectiveness of integrated treatment was conducted in a randomized study of 55 patients with inflammatory diseases of the lower section of the urogenital tract, which in the cervical canal by polymerase chain reaction (test system Interlabservice Moscow) were detected chlamydia, Mycoplasma, Ureaplasma, were randomly divided into two groups; 1 group (comparison) (n=27) provided the patients who were treated using the basic scheme using etiotropic therapy, 2nd group (main) (n=28) consisted of patients who a comprehensive outline of local and systemic therapy were included local impact magneto laser. All the patients were comparable in terms of social status, age, lack of extras is genital pathology, methods of contraception, the source of infectious-inflammatory process. For the distribution of patients depending on its source and the localization of the inflammatory process, we used the ICD-10 classification, highlighting cervicitis N-72 (20% in the first group and 23% in the second), ectopia of the cervix (35% in the first group and 37% in the second).

During the study all patients were studied in a number of clinical features, allowing us to assess the dynamics of the inflammatory process and the General condition of the patients: the disappearance of hyperemia of mucous membranes of the urogenital tract, infiltration, regional infiltration at the periphery of the erosion, termination exudation, purification of the cervical canal from necrotic masses, swelling of the mucous.

For an objective assessment of the inflammatory process and the nature of the immunological changes in the area of inflammatory lesion were conducted special research methods: 1) cytological study in the area of inflammatory process, material was collected by the method of "superficial biopsy, was calculated percentage (%) neutrophil count before treatment and after treatment; 2) the study of the immune factors of cervical secret - estimated the total number of white blood cells, absolute and relative content of viable cells in 1 l of secret. Because neutrophils was dominiruyushie and cells in these secrets, conducted in-depth analysis of their functional activity, the calculation of the total luminescence of lysosomes in conventional units. Phagocytic activity of neutrophils was studied on the model of the uptake of latex particles, the study of spontaneous and induced oxybiotic metabolism of neutrophils was detected in the sample from nicrosini tetrazolium (NBT-reducing activity and intensity). Also determined the level of immunoglobulin a, M, G, lysozyme, nonspecific esterase neutrophils of cervical secretion, total hemolytic activity (CH-50), components of the complement of cervical secretion and the concentration of cytokines (IL-1, IL-8, TNF-α. IFN-γ) by the method of solid phase ELISA (LLC "Cytokine",St. Petersburg), in accordance with the test system instructions. The data processed by methods of variation statistics were expressed as arithmetic mean and its standard error (M±m), n is the number of observations in the sample. The research results were processed using the software package "Statistica for Windows".

The results of the study showed that those patients who had local impact magneto laser with a therapeutic purpose in significantly earlier than patients with traditional local treatment, we observed the disappearance of signs of inflammation (3,50±0,30) day. Patsie the current comparison group improvement occurred in the of 5.50±0.20 day, the disappearance of regional infiltration at the periphery of the inflammatory focus (4,50±0,15 and 6.50±0,23) days, respectively, cleansing inflammatory focus from necrotic masses (4.10±0.20 day when treatment with application of magnitolazeroterapii and 5,90±0,20 when etiotropic treatment).

In the process of studying the influence of local magnitolazeroterapii at the cellular composition of the inflammatory lesion found the following: when treatment with the use of magnetic effects already on day 3 or 4 in the area of inflammation was noted active change of the phases of the inflammatory process, with a significant decrease in the relative number of neutrophils. By the end of treatment the General appearance of cytogram was defined as regenerative. While patients treated without the use of magnitolazeroterapii, and 10 day preserved signs of exudative inflammation (table 1, 2, 3).

The study of the dynamics and speed of normalization of immune factors in cervical secretion revealed a restoration of the functional activity of neutrophils of cervical mucus, the concentration of proinflammatory cytokines, immunoglobulins a, M, G, secretory immunoglobulin a in cervical secretions, severe dysfunction have been identified in patients before treatment (compared with clinically healthy donors). In the process of treatment in the group PR is treated using magneto laser differences in immunological parameters on the values of healthy women was not, whereas in patients receiving local treatment, remained local signs of immunodeficiency (for example, the concentration of sIgA in the group of "Healthy" amounted to 1.05 g/l in the group treated without the use of physiotherapy and 1.35±0.17 g/l (with significance of differences with healthy p=0.0014), in the group where the basic treatment was combined with the local magnetic-laser therapy of 1.10±0.15 g/l, without significant differences with the control group). Thus, the authors conducted studies revealed immunological efficacy of a new method of treatment - local immune disorders using magnetic effects in complex treatment of inflammatory diseases of the lower section of the urogenital tract caused by microorganisms, sexually transmitted diseases.

To illustrate the clinical and immunological effect of local application of magnitolazeroterapii driven clinical examples.

Example No. 1. Sick And VA AV, 30 years, the diagnosis of inflammatory disease of the urinary tract caused clarified bacterial agent (M.hominis, M.genitalium, U. Urealyticum) - 96.8 and chlamydial infection of genitourinary tract without complications And 56.0". When contacting the patient complained of pus-slimy character. When viewed from the urethra was revealed: swelling and redness of the mucous membranes of urogenital the th path, the mucous membrane in the area of the transition zone was edematous, hyperemic, there has been a considerable amount of purulent mucus, expressed pastos and swelling of the urethra, painful urination. During the inspection was made on biopsy specimens for microbiological testing and immunological and cytological study. Data cytological, immunological studies of cervical secret:

1) in smears-cervical scrapings of the channel was determined exudative inflammatory type cytogram - relative content of neutrophils in 92%, macrophage - 5%, lymphocytes - 2%;

2) the study of cervical secret: leukocytes - 7.29×109/l; leukocytes viable - 68.22%; leukocytes viable - 4.88×109; lysosomal activity of neutrophils - 20.76%; lysosomal activity of neutrophils - 19.60$..; nst-test spontaneous - 45.78%; nst-test spontaneous - $ 0.65; nst-test-induced - 60.35%; nst-test-induced - 0.82 USD, the functional reserve of neutrophil - 1.37; activity of neutrophil phagocytosis - 45.75%; activity of neutrophil phagocytosis - $ 1.65, nonspecific esterase - 24.61%; nonspecific esterase - 0.3 cu; SN-50 - $ 49.23; C1 - 43.38 Eph. mol/ml; C2 - 29.52 Eph. mol/ml; C3 - 33.32 Eph. mol/ml; C4 - 18.25 Eph. mol/ml; C5 - 26.18 Eph. mol/ml; Ig And - 0.71 g/l; Ig M - 0.28 g/l; Ig G - 1.08 g/l; Ig And secretory - 0.75 g/l; lizol is - 28.55 µg/ml; the content of IL-1α - 2.38 PG/ml; levels of IL-1β - 1.22 PG/ml; the content of TNF-α - 2.47 PG/ml; the content of the receptor antagonist IL-1 - 1.26 PG/ml; the content of the cytokine IL-8 - 0.97 PG/ml; the content of interferon IFN-γ - 0.018 PG/ml, the Patient received a comprehensive medication: daily, starting from the first day of therapy: cold 2 ml intramuscularly, claforan 1 g 2 times a day, vilprofen 500 mg 3 times a day, trichopol 0.25 mg 2 times a day, vitamins 1 time per day; local therapy: candles "henderon and macmiror complex" 1 time daily vnutrivlagalischno through the day; local therapy: the cervical canal irrigation and urethral instillation of 0.1% chlorhexidine digluconate, tampons 2% "Dalacin cream 2%" 6 hours - 10 treatments; rehabilitation therapy: candle Azilect No. 10. Magnetic-laser therapy from the 1st day of treatment No. 10. The disappearance of infiltration, reducing the number of detachable marked on 5-6 day, hyperemia of the mucous membrane on the 4th day, in the same period was determined by the improvement of the General condition. The patient with an improvement in a satisfactory condition, has been charged with follow-UPS after treatment. The results of cytological examination of smears of scrapings from the cervical canal, immunological studies of cervical secretion after treatment:

1. In smears the relative content of nathrop the crystals - 53%, lymphocytes - 35%, macrophage - 12%.

2. Immunological study of cervical secret: leukocytes - 7.57×109/l; leukocytes viable - 62.79%; leukocytes viable - 5.31×109; lysosomal activity of neutrophils - 16.38%; lysosomal activity of neutrophils - $ 19.46; nst-test spontaneous - 46.10%; nst-test spontaneous - $ 0.33; nst-test-induced - 62.95%; nst-test-induced - $ 0.68; functional reserve of neutrophils - 1.37; activity of neutrophil phagocytosis - 46.38%; activity of neutrophil phagocytosis - $ 1.82; nonspecific esterase - 27.43%; nonspecific esterase - 0.33 cu; SN-50 - $ 48.49, C1 - 43.35 Eph. mol/ml; C2 - 29.67 Eph. mol/ml; C3 - 38.45 Eph. mol/ml; C4 - 17.75 Eph. mol/ml; C5 - 26.28 Eph. mol/ml; And - 0.57 g/l; Ig M - 0.30 g/l; Ig G - 1.02 g/l; Ig And secretory - 0.83 g/l; lysozyme - 30.89 µg/ml; the content of IL-1α - 2.46 PG/ml; levels of IL-1β - 1.39 PG/ml; the content of TNF-α - 2.44 PG/ml; the content of the receptor antagonist IL-1 - 2.05 PG/ml; the content of the cytokine IL-8 - 0.90 PG/ml; the content of interferon IFN-γ - 0.020 PG/ml.

Example No. 2. Sick In about A.G., 32 years old, the diagnosis of inflammatory disease of the urinary tract caused clarified bacterial agent (M.hominis), 96.8 and chlamydial infection of genitourinary tract without complications And 56.0". When contacting the patient complained of pus-slimy character within 10 days. When viewed retrival identified pastos and swelling, edema and hyperemia of the mucosa in the area of the transition zone was swollen, moderately hyperemic, in the rear arch has been a considerable amount of purulent mucus, the patient was noted painful urination. After examination and analysis of results of laboratory studies course started comprehensive antibacterial and magnitolazeroterapii. During the inspection was made on biopsy specimens for microbiological testing and immunological and cytological study. Data cytological, immunological studies of cervical secret:

1. In smears-cervical scrapings of the channel was determined exudative inflammatory type cytogram - relative content of neutrophils in 96%, macrophage - 2%, lymphocytes - 2%;

2. Study of cervical secret: leukocytes - 7.26×109/l; leukocytes viable - 68.20%; leukocytes viable - 4.80×109; lysosomal activity of neutrophils - 20.7%; lysosomal activity of neutrophils - $ 19.20; nst-test spontaneous - 45.71%; nst-test spontaneous - $ 0.63; nst-test-induced - 60.30%; nst-test-induced - $ 0.80; functional reserve of neutrophils - 1.33; activity of neutrophil phagocytosis - 45.70%; activity of neutrophil phagocytosis - $ 1.69; nonspecific esterase - 24.63%; nonspecific esterase - 0.4 cu; SN-50 - $ 49.2; C1 - 43.40 Eph. mol/ml; C2 - 29.53 Eph. mol/ml; C3 - 33.34 Eph. mol/ml; C4 - 18.23 Eph. mol/ml; C5 - 26.15 Eph. mol/ml; immunoglobulin And - 0.73 g/l; Ig M - 0.27 g/l; Ig G - 1.07 g/l; Ig A - 0.73 g/l; lysozyme gained 28.53 µg/ml; the content of IL-1α - 2.37 PG/ml; levels of IL-1β - 1.21 PG/ml; the content of TNF-α - 2.46 PG/ml; the content of the receptor antagonist IL-1 - 1.25 PG/ml; the content of IL-8 - 0.98 PG/ml; the content of interferon IFN-γ - 0.017 PG/ml, the Patient received a comprehensive medication: daily, starting from the first day of therapy: cold 2 ml intramuscularly, claforan 1 g 2 times a day, vilprofen 500 mg 3 times a day, trichopol 0.25 mg 2 times a day, vitamins 1 time per day; local therapy: candles "henderon and macmiror complex" 1 time daily vnutrivlagalischno through the day; local therapy: the cervical canal irrigation and urethral instillation of 0.1% chlorhexidine digluconate, tampons 2% "Dalacin cream 2%" 6 hours - 10 treatments; rehabilitation therapy: candle Azilect No. 10. The magnetic-laser therapy was performed using an apparatus "Mustang 2000". Used the following parameters exposure: magnetic field intensity 1.25 Tesla; frequency series of pulses per minute 30, the interval between the pulses of 100 MS; the wavelength 0.63 μm, the mode - constant. Position the patient is lying in the gynecological chair or on the couch on his back, legs bent at the knee and hip joints and divorced irradiation Duration was 5 minutes. The course of treatment consisted of 10 treatments impact Localization: radiant head with a nozzle has failed to contact the cervix Nude using a speculum, the exposure time is 5 minutes. The results of cytological and immunological examination of cervical secret:

1. Smears were determined regenerative type cytograms - relative content of neutrophils - 51%, lymphocytes - 15%, macrophage - 26%, fibroblast - 6%;

2. Immunological study of cervical secret: leukocytes - 6.69×109/l; leukocytes viable - 62.79%; leukocytes viable - 5.39×109; lysosomal activity of neutrophils - 24.12%; lysosomal activity of neutrophils - $ 32.50; nst-test spontaneous - 30.08%; nst-test spontaneous - $ 0.42; nst-test-induced - 60.23%; nst-test-induced - $ 0.80; functional reserve of neutrophils - 1.97; activity of neutrophil phagocytosis - 57.58%; activity of neutrophil phagocytosis - $ 2.31; nonspecific esterase - 29.59%; nonspecific esterase - 0.34 cu; SN-50 - $ 48.34; complement components C1 - 43.82 Eph. mol/ml; C2 - 46.72 Eph. mol/ml; C3 - 33.72 Eph. mol/ml; C4 - 18.12 Eph. mol/ml; C5 - 25.85 Eph. mol/ml; Ig And - 0.54 g/l; Ig M - 0.28 g/l; Ig G - 0.93 g/l; Ig And secretory - 0.85 g/l; lysozyme - 40.22 µg/ml; the content of IL-1α - 3.14 PG/ml; levels of IL-1β - 2.03 ng/ml; the content of TNF-α - 2.81 PG/ml; the content of the receptor antagonist IL-1 - 3.39 p is/ml; the content of the cytokine IL-8 - 0.85 PG/ml; the content of interferon IFN-γ - 0.020 PG/ml.

Example No. 3. Patient C-o A.G., 34, the diagnosis of inflammatory disease of the urinary tract caused clarified bacterial agent (M.hominis), 96.8 and chlamydial infection of genitourinary tract without complications And 56.0". When contacting the patient complained of pus-slimy character within 10 days. During the inspection of the urethra was found pastos and swelling, edema and hyperemia of the mucosa in the area of the transition zone was swollen, moderately hyperemic, in the rear arch has been a considerable amount of purulent mucus, the patient was noted painful urination. After the inspection began a course of combined antibacterial and magnitolazeroterapii. During the inspection was extracted material for immunological and cytological study:

1. Data cytological, immunological studies of cervical secretion, in the discharge smears - cervical scrapings of the channel was determined exudative inflammatory type cytogram - relative content of neutrophils in 96%, macrophage - 2%, lymphocytes - 2%;

2. Study of cervical secret: leukocytes - 7.27×109/l; leukocytes viable-68.23%; leukocytes viable - 4.81×109; Lisa amalina activity of neutrophils - 20.80%; lysosomal activity of neutrophils - $ 19.10; nst-test spontaneous - 45.70%; nst-test spontaneous - 0.62 conventional units; nst-test-induced - 60.1%; nst-test-induced - $ 0.81; functional reserve of neutrophils - 1.34; activity of neutrophil phagocytosis - 45.72%; activity of neutrophil phagocytosis - 1.68. E.; nonspecific esterase - 24.61%; nonspecific esterase - 0.3 cu; SN-50 - 49.1 conventional units; complement components C1 - 43.40 Eph. mol/ml; C2 - 29.51 Eph. mol/ml; C3 - at 33.31 Eph. mol/ml; C4 - 18.23 Eph. mol/ml; C5 - 26.14 Eph. mol/ml; Ig And - 0.73 g/l; Ig M - 0.27 g/l; Ig G - 1.07 g/l; Ig And secretory - 0.73 g/l; lysozyme gained 28.53 µg/ml; the content of IL-1α - 2.37 PG/ml; levels of IL-1β - 1.22 PG/ml; the content of TNF-α - 2.45 PG/ml; the content of the receptor antagonist IL-1 - 1.24 PG/ml; the content of the cytokine IL-8 - 0.99 PG/ml; the content of IFN-γ - 0.016 PG/ml, the Patient received a comprehensive medication: daily, starting from the first day of therapy: cold 2 ml intramuscularly, claforan 1 g 2 times a day, vilprofen 500 mg 3 times a day, trichopol 0.25 mg 2 times a day, vitamins 1 time per day; local therapy: candles "henderon and macmiror complex" 1 time daily vnutrivlagalischno through the day; local therapy: the cervical canal irrigation and urethral instillation of 0.1% chlorhexidine digluconate, tampons with 2%, Dalacin cream 2%by 6 hours - 10 treatments; rehabilitation therapy: the light and Azilect No. 10. The magnetic-laser therapy was performed using an apparatus "Mustang 2000". Used the following parameters exposure: magnetic field intensity 1.25 Tesla; frequency series of pulses per minute 30, the interval between the pulses of 100 MS; the wavelength 0.63 μm, the mode of the radiation constant. Position the patient is lying in the gynecological chair or on the couch on his back, legs bent at the knee and hip joints and divorced. The duration of exposure was 5 minutes. The course of treatment consisted of 10 sessions. Impact localization: radiant head with a nozzle fail to contact the cervix Nude using a speculum, which during the procedure you want to delete, irradiate the cervix in for 5 minutes. The results of cytological, immunological examination of cervical secret:

1. Smears were determined regenerative type cytograms - relative content of neutrophils - 51%, lymphocytes - 15%, macrophage - 26%, fibroblast - 6%;

2. Immunological study of cervical secret: leukocytes - 6.67×109/l; leukocytes viable - 62.79%; leukocytes viable - 5.39×109; lysosomal activity of neutrophils - 24.12%; lysosomal activity of neutrophils - 32.5 cu; nst-test spontaneous - 30.07%; nst-test spontaneous - $ 0.41; nst-test-induced - 60.24%; nst-test-induced - 0.81 is e; the functional reserve of neutrophil - 1.96; activity of neutrophil phagocytosis - 57.58%; activity of neutrophil phagocytosis - $ 2.31; nonspecific esterase - 29.58%; nonspecific esterase - 0.34 cu; SN-50 - $ 48.34; complement components C1 - 43.81 Eph. mol/ml; C2 - 46.72 Eph. mol/ml; C3 - 33.72 Eph. mol/ml; C4 - 18.12 Eph. mol/ml; C5 - 25.85 Eph. mol/ml; Ig And - 0.54 g/l; Ig M - 0.28 g/l; Ig G - 0.93 g/l; Ig And secretory - 0.85 g/l; lysozyme - 40.21 µg/ml; the content of IL-1α - 3.14 PG/ml; IL-1β - 2.02 ng/ml; TNF-α - 2.83 ng/ml; receptor antagonist IL-1 - 3.39 PG/ml; IL-8 - 0.84 PG/ml; interferon IFN-γ - 0.021 PG/Jr. tested the proposed method of complex therapy confirmed its advantages over the method of the prototype: unlike the prototype method in the process of local treatment using magnitolazeroterapii there is a complete normalization factors of local immunity - increases the functional activity of neutrophils of cervical secretion, restores the balance of the mucosal immune factors, increases the action of etiotropic therapy and accelerated elimination of the pathogen, preventing re-contamination of the urethra and vagina nosocomial flora. In this way, the proposed method of treatment improves immunological efficacy of complex treatment of patients with infectious and inflammatory diseases of ur of the genital tract, caused by microorganisms, sexually transmitted diseases

Literature

1. Allenes S.N. Immunological aspects of the use of polyoxidonium in complex therapy of complicated urogenital chlamydia / Snilow, Alifanov, Kamolov etc. // ROS. Journe. skin and venereal diseases. - 2002. No. 2. - P.58-61.

2. Anupana I.S. Mixed chlamydial infection and immunotherapy / Isanapura, Apelsinas // journal of dermatology and venereology. No. 1. - 2005. - S. 28-30.

3. Anupana I.S. Pathogenetic substantiation corrective therapy of patients with chlamydial Trichomonas infection / Isanapura, Dpeterson, Appeltans // all-Union Congress of Dermatovenereology, 9th. - M., 1991. - P.6-7.

4. Bartenev NS Questions of immunity in chlamydial infections / Nesvarenie // Chlamydial infection: Sat. scient. Tr. Ed. Ada. - M., 1986. - P.14-20.

5. Belyakov IM Immune system mucous / Yemelyanov // Immunology. - 1997. No. 4. - P.7-13.

6. A.A. Burov Basic properties of the pathogen chlamydia and its role in the development of infections of the urogenital tract / ABV, Saadulaev, Energynow // Ukr. Microbiology, epidemiology and Immunobiology. - 1999. No. 4. - S.

7. Gomberg M.A. Rationale for immunotherapy in the treatment of recurrent urogenital chlamydia / Masonberg, Amolofeev, Adderrose // Infection, transmitted p is viewed by. - 2004. No. 2. - P.30-33.

8. Dolgushin I.I. Neutrophils and homeostasis / Dry, Avebury. - Ekaterinburg, 2001, - 258 C.

9. Jonas A.P. techniques of laser therapy for red and infrared lasers operating in continuous wave and pulsed operation modes / Apigenin // Methodological materials, ahmado; Chelyabinsk, 1995, to 80 C.

10. Cosel A.I. Mechanism of action of laser irradiation on tissue and cellular levels / Aigoul, Gckpou // Vestnik St.Petersburg University. The RAMS. - 2000. No. 2. - P.41-43.

11. Medvedev B. I. Peculiarities of local immunity when associated with chlamydia chronic inflammatory diseases of the pelvic organs in women / bi Medvedev, Aaaaaa, Elizatko // Ukr. Microbiology, epidemiology and Immunobiology. - 2000. No. 2. - S.89-92.

12. Molochkov VA Urogenital chlamydiosis. Clinic, diagnostics, treatment. / Vasilkov // MONICA them. Vladimir. - M., 2001, to 10 C.

The way the local immune, infectious and inflammatory diseases of the urogenital tract, caused by microorganisms, sexually transmitted diseases, on the background of a comprehensive drug treatment, characterized in that as an immunomodulating effects from the first day of treatment effect magnetic radiation to the cervix, sending m is nitrazine impact directly into the cervical canal, moreover, the use of low intensity laser with variable pulse generation, when the intensity of the magnetic field of 1.25 T, the frequency of a series of impulses per minute 30, the interval between pulses of 100 MS duration of exposure 5 min, for this cervix strip using a speculum, which during the procedure are removed, the treatment course of 10 treatments.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to veterinary science. The agent contains, wt %: 17α-Acetoxy-3β-butanoyloxy-6-methylpregna-4,6-dien-20-one - 0.5, ethinylestradiol - 0.02, vegetable oil (soya oil) - up to 100.

EFFECT: agent is highly effective for the purpose of oestrus control.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to veterinary science. The agent contains, wt %: 17α-Acetoxy-3β-butanoyloxy-6-methylpregna-4,6-dien-20-one 0.120, ethinylestradiol - 0,001, vegetable oil - up to 100.

EFFECT: means is highly effective for oestrus control in female cats and dogs, the use thereof enables lowering a probability of the onset and the intensity of side effects.

2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a diacetate of racemic 18-ethyl-gona-1,3,5(10),8(9)-tetraene-3,17β-diol, having anti-implantation and antioxidant activity with low uterotropic action. Presence of antioxidant activity in said steroid is essential since compounds with such action can be agents for preventing oestrogen-dependent breast cancer.

EFFECT: compounds exhibit anti-implantation and antioxidant activity with low uterotropic action, which is an advantage over agents used in practice.

1 cl, 1 ex, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to pharmaceutics and medicine, and concerns application of sophoricoside.

EFFECT: preparing the drug applicable for preventing and/or treating articular cartilage degeneration or osteoarthritis in postmenopausal females, exhibiting side-effect-free high efficacy.

6 cl, 11 dwg, 5 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is offered is a pharmaceutical composition for local application in gynaecology and containing therapeutically effective amounts of ornidazole, neomycin or gentamycin, an anti-inflammatory ingredient specified in a group of glucocorticosteroids, and an antimycotic ingredient specified in imidazole derivatives.

EFFECT: invention provides producing a new preparation for intravaginal therapy of infectious-inflammatory and disbiotic genital diseases in females.

5 cl, 8 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely dermatovenerology and is applicable for treating chronic infectious urethritis complicated by prostatitis. That is ensured by taking azithromycin 1.0 g (sumamed) once a day in 1st-7th-14th days combined with the complex therapy. The complex therapy involves rectal suppositories Dalargex, 1 suppository daily at bedtime No.10, prostate massage, rectal laser therapy and daily application of fluoroquinolone - gemifloxacin (factive) 1 tab. (320 mg) a day for 14 days.

EFFECT: method enables prolonged remission of the disease, higher life quality of the patients, recovers the reproductive function due to improved eradication of the opportunistic flora in the prostate secretion contents.

4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, obstetrics, gynecology and includes estimation of puerperas' state, depending on which treatment tactics is selected. Severity of state is estimated by two groups of criteria of table No 3, presented in the description, by 1 point: absence of factors of risk of purulent-septic complications (PSC), subfebrile condition with single rise to 38°C, arrested by antibacterial therapy (ABT), absence of easily arrested intestine paresis after Cesarean section, the cervix of uterus is formed, presence of uterus involution in hysteroscopy at the background of treatment with endometrectomy or vacuum-aspiration, USE-data - increase and extension of uterus cavity by 0.5-1.0 cm, absence of deformation in the area of scar or deformation up to 0.5 cm, on uterus walls - linear echo-positive structures up to 0.2-0.3 cm thick, local sections of reduced myometrium echogenicity in the region of scars not larger than 1.5x1.5 cm, absence of infiltration, hematoma in the region of scars, improvement of laboratory indices in dynamics. Criteria of group 2 are estimated in 2 points: presence of PSC risk factors, long-lasting fever with resumption after finishing ABT, intestine paresis with absence of effect from intensive or repeated treatment courses, absence of tendency to formation of uterus cervix, stable uterus subinvolution, by USE data: extension of uterus cavity ≥1 cm, deformation in scar ≥0.5 cm, echopositive structures ≥0.4 cm, reduces echogenicity in scar zone ≥2.5×1.5 cm, hematoma or infiltrate in retrovesical space, in area of scars, absence of positive dynamics or change of laboratory indices to the worse. If state of puerpera is characterised by criteria of the first group to 7 points, it is estimated as uncomplicated form of disease, if - more than 7 points or at least by one criterion from group 2, as complicated form.

EFFECT: method ensures reliable justification of adequate tactics of patient management, strict control of their state in dynamics, reduction of frequency of complicated generalised forms of PSC, terms of staying in hospital.

2 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: method involves simulating gestosis in Wistar rats by the daily intraperitoneal introduction of L-nitro-arginine-methyl ester 25 mg/kg for 14th to 20th day of pregnancy. Gestosis is corrected by using the daily intragastric introductions of L-norvaline 10 mg/kg once a day with underlying simulation for 7 days.

EFFECT: method provides manifested correction of placental microcirculation disorder ensured by increasing L-arginine availability for NO synthesis.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to substituted heteroarylpiperidine derivatives of formula (I) and enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof, where R1 denotes -N(R10)-(C(R6)2)m-T, (C(R6)2)1-T or -O-(C(R6)2)m-T; R6 is independently selected from H, OCH3, C1-6-alkyl, possibly substituted with 1-3 substitutes which are halogen, and C3-6-cycloalkyl, possibly substituted with 1-3 substitutes which are halogen, T denotes NR7R8, , , , or ; R7 and R8 are independently selected from H, C1-6-alkyl; R9 is independently selected from OH, C1-6-alkyl, O-C1-6-alkyl, or NR12R13; R10 denotes H or C1-6-alkyl; R12 and R13 are independently selected from C1-6-alkyl, possibly substituted with OH, C2-6-alkylene-O-C1-6-alkyl and W denotes CH, O or NR10; B denotes CR2 or N; G denotes CR2 or N; D denotes CR2 or N; E denotes CR2 or N; provided that one or more of variables B, G, D and E must be N; R2 is independently selected from H, F, Cl, CH3, OCH3 and CF3; R3 denotes: H, CI, F or CH3; R4 denotes Cl, F or CH3, R5 denotes , morpholine, possibly substituted with 1-3 identical or different substitutes R14, a 4-7-member saturated or partially unsaturated heterocycle containing one nitrogen atom in the ring and possibly an additional heteroatom selected from O, N and S, where the heterocycle is possibly substituted with 1-4 identical or different substitutes R11, or NR12R13; R11 is indendently selected from halogen, OH, C1-6-alkyl, possibly substituted with 1-3 substitutes which are halogen, C2-6-alkynyl, -C0-6-alkyl-C3-6-cycloalkyl, -OC(O)C1-6-alkyl, -NH2, -NH(C1-6-alkyl) and -N(C1-6-alkyl)2; A denotes a 3-7-member saturated ring; R12 and R13 are independently selected from C1-6-alkyl, possibly substituted with OH, C2-6-alkylene-O-C1-6-alkyl; R14 denotes C1-6-alkyl; 1 equals 0, 1, 2, 3 or 4; m equals 0, 1, 2, 3 or 4; o equals 0, 1 or 2; p equals 0, 1, 2, 3 or 4; r equals 0, 1, 2, 3 or 4; s equals 1 or 2 and t equals 0 or 1. The invention also relates to use the compound of formula I to produce a drug for treating or preventing disorders, diseases or conditions responsible for inactivation or activation of the melanocortin-4 receptor in mammals, and to a pharmaceutical composition based on said compounds.

EFFECT: novel compounds which can be used as melanocortin-4 receptor modulators are obtained and described.

10 cl, 134 ex, 16 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gynaecology, and is applicable for treating patients with refractory pregnancy loss in the first trimester. That is ensured by prescribing a water solution of the preparation Immunal 1 dosimetric pipette twice a day, tablets of nicotinic acid 50 mg twice a day, rectal enemas with 30% sodium thiosulphate 5.0 ml and 0.25% Novocain 15.0 ml once a day, and Rekicene-RD one dessertspoon twice a day. The therapeutic course makes 30 days.

EFFECT: method provides higher clinical effectiveness and prevented complications due to complex immunomodulatory, anti-inflammatory, disintoxication effect improving blood circulation.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacy, namely technology of preparation of rectal suppositories. The suppositories with solid licorice extract consist of solid licorice extract 0.75 g on a hydrophilic base, polyethylene glycol 6000 1.25 g and polyethylene glycol polystear 0.25 g.

EFFECT: making the preparations exhibiting anti-inflammatory action, and also a positive effect on the hormonal status and the copulative function.

7 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to herbal medicine. There are presented a preparation and a method for making it for the purpose of improving the functional urinary condition, containing an oil extract of juniper fruits, common valerian root and rhizomes, elecampane inula roots, creeping thyme herb, marjoram herb and strawflower blossom, a dry aqueous or aqueous-alcoholic extract prepared from extracts of the same vegetable ingredients after the oil extraction, and linen oil.

EFFECT: preparation improves the urinary condition and is applicable as an additional therapy in the patients suffering non-complicated clinical course of active chronic pyelonephritis and acute cystitis, and also within a complex therapy of the patients suffering chronic cholecystitis and biliary dyskinesia, and within a long-term therapy in the patients with various forms of osteoarthrosis, including arthritic one.

8 cl, 2 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely urology, is applicable for treating chronic cystitis. That is ensured by drug instillations into a bladder. In addition, the instillation is preceded by endovesical mucosal exposure to laser light of wave length 0.62 mcm. The instillation is followed by pubic exposure to laser light of wave length 0.86 mcm within a projection of the bladder. The duration of each procedure is 7 minutes; the therapeutic course is 10-12 procedures.

EFFECT: method provides higher clinical effectiveness ensured by pain pulse interruption and improved microcirculation and consequently prolonged drug staying in the bladder cavity as a result of the exposure to laser light before the instillation, and also by deeper drug penetration in bladder tissue as a result the epicutaneous exposure to laser light after the instillation.

1 dwg, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine and concerns an agent for preventing, treating and/or relieving a symptom of dysuria, containing a compound of formula (1) showing high activity.

EFFECT: preparing the agent for preventing, treating and/or relieving the symptom of dysuria.

7 cl, 2 dwg, 3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of formula

, where X1, X2, Y, R1a, R1b, R2a, R2b, A1, A2, A3 and A4 have the values specified in the description, which are vanilloid receptor subtype 1 (VR1) antagonists.

EFFECT: preparing a pharmaceutical composition on the basis of the compounds of formula 1 and developing methods of managing pain, neurotic pain, allodynia, inflammation or inflammatory disease associated pain, inflammatory hyperalgesia, bladder hyperactivity and urine incontinence.

22 cl, 21 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly urology, and may be used for treating endotoxicosis in acute-on-chronic pyelonephritis. That is ensured by three introductions of ceruloplasmin 5 mg/kg every third day with underlying introduction of antibiotics.

EFFECT: method allows decreasing a degree of intoxication due to reducing a number of medium molecular weight peptides and leukocytic intoxication index in blood plasma, and also decreasing erythrocyte sedimentation rate.

1 ex, 3 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is offered is applying 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine (V0162), as well as its pharmaceutically acceptable salts for preparing a drug applicable for treating or preventing urinary incontinence and related disorders caused by bacterial or mycotic infections developed due to cystic hyperactivity by means of selective inhibition of M1, M2- and M3-muscarine receptors in local and/or oral application.

EFFECT: V0162 decreases intracystic pressure, promotes anticholinergic action in vivo, effectively passes through a mucous membrane, reaching the levels involved in its anticholinergic activity, and when delivered locally has no toxic action neither histologically relation, nor with respect to the vital functions: respiratory rate, pulse, behaviour.

8 cl, 5 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel acid-additive salts of pyrrolopyrimidinone derivative, represented by formula (1) which is selected from gentisate, maleate, citrate, fumarate and semitartrate salts, which possess improved properties in their application, in particular higher stability.

EFFECT: invention also relates to method of obtaining acid-additive salts of pyrrolopyrimidinone derivative, represented by formula (1) and to pharmaceutical composition, containing them, for treatment and prevention of erectile dysfunction, pulmonary arterial hypertension, chronic obstructive lung disease, benign prostate gland hypertrophy and diseases of lower urinary tract.

11 cl, 30 ex, 7 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared group of inventions relates to medicine. There are declared methods of treatment and preventive treatment of prostate cancer in males and a method for treatment of prostate cancer in male dogs involving a single agent therapy in the form of introducing a therapeutic amount of N,N'-bis(2,3-butadienyl)-1,4-butane-diamine or its pharmaceutically acceptable salt or solvate. The therapeutic amount is specified within the range from 1-100 mg/kgbody weight and dosed within the range from twice a week to once a day.

EFFECT: group of inventions has high therapeutic efficacy.

26 dwg, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to azabenzofuranyl compounds of formula I and salts thereof, where: Z1 denotes CR1, Z2 denotes N, Z3 denotes CR3, Z4 denotes CR4, R1, R3 and R4 are independently selected from H, halogen, CN, -(CR14R15)nC(=Y)OR11, - (CR14R15)nOR11, C1-C12 alkyl; W denotes or R5 and R6 are independently selected from H or C1-C12 alkyl; X1 is selected from R11, -OR11 and -S(O)2R11; if X1 denotes R11 or -OR11 from X1 and -R5 optionally taken together with a nitrogen atom with which they are bonded form a 4-6-member saturated or unsaturated ring containing 0-2 additional heteroatoms selected from O, S, where said ring is optionally substituted with one or more groups selected from oxo, -(CR19R20)nNR16R17, -(CR19R20)nOR16, (CR19R20)nS(O)2R16 and R21; X is selected from aryl, where said aryl is optionally substituted with one or more groups selected from halogen, CN, -Si(C1-C6alkyl), -(CR19R20)nOR16, -(CR19R20)nSR16, C1-C12alkyl; R11, R12 and R13 independently denote H, C1-C12alkyl, aryl, azetidine, pyrrolidinyl, piperidinyl, tetrahydropyranyl; R14 and R15 are independently selected from H or C1-C12 alkyl; n is independently selected from 0, 1; Y independently denotes O; where each of said alkyl, alkenyl, aryl and heteroaryl from R1, R2, R3, R4, R5, R6, X1, X2, R11, R12, R13, R14 and R15 is independently and optionally substituted with one or more groups independently selected from -(CR19R20)nC(=Y')OR16, -(CR19R20)nNR16R17, -(CR19R20)nOR16, -(CR19R20)nNR16C(=Y')R17, -(CR19R20)nNR16C(=Y')OR17, - (CR19R20)nNR17SO2R16 and R21; each R16, R17 independently denotes H, C1-C12 alkyl, C2-C8alkenyl, aryl, or pyridinyl, where said alkyl, alkenyl or aryl is optionally substituted with one or more groups selected from -OH; R19 and R20 are independently selected from H, C1-C12 alkyl; R21 denotes C1-C12 alkyl, aryl, imidazolyl, pyridinyl, pyrazolyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperidinyl, or 2,2-dimethyl-1,3-dioxolanyl; each Y' independently denotes O. The invention also relates to specific compounds, a pharmaceutical composition based on the disclosed compounds, a method of inhibiting anomalous cell growth or a method of treating hyperproliferative disorders, inflammatory diseases and other diseases.

EFFECT: novel azabenzofuranyl derivatives which can be used in treating cancer and inflammatory diseases are obtained.

23 cl, 3 tbl, 34 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and veterinary science. A method involves sequential intravenous introduction of a binary catalytic system (BCS): an oxidation catalyst - a metal complex and an oxidation substratum - ascorbic acid (AA). The oxidation catalyst is introduced in a maximally tolerable or lower doses, and AA - in doses related to molar ratio of the metal complex: AK=1:10. The method also involves local hyperthermia of the tumour with using near infra-red laser emission. The tumour temperature is maintained within the range of 43-45°C by adjusting laser power density. The emission is terminated after achieving the minimum power density maintaining the tumour temperature within the preset temperature range. The declared device comprises a near infra-red laser with emissive power switch-on, switch-off and adjustment systems, and optical system of laser beam formation, a tumour temperature control system with its output connected both with an input of a laser negative feedback system, a laser power density control system. The device comprises an additionally adjustable power density discriminator. An input of the laser power density discriminator is connected with an output of the laser power density control system. The output of the discriminator is connected to an input of the laser switch-off system.

EFFECT: invention provides higher clinical effectiveness.

5 cl, 1 dwg, 1 ex

Up!